MedinCell S.A. announced that following positive results of in vivo studies, the Bill & Melinda Gates Foundation has confirmed its support to pursue the formulation research of a 6-month active contraceptive. The objective is to enter non-clinical development in 2020 and then clinical development. MedinCell has been awarded a $3.5 million grant by the Bill & Melinda Gates Foundation to fund the formulation research phase of this program. A first tranche of $2 million was received at the start of the program in November 2017, and the second of $1.5 million has just been received following promising first in vivo results.